Clinical Trials in Pittsburgh

Showing 5581-5600 of 16,007 trials

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

NCT04408599

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsOvarian CancerGastric Cancer+1 more

NextCure, Inc.46 participantsStarted Jun 2020

Bethesda, Maryland, United States • Hackensack, New Jersey, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 356 miles

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT02773849

Previous multi-dose Phase I and Phase II clinical studies have demonstrated that ADSTILADRIN is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of ADSTILADRIN in patients that are "BCG Unresponsive" which refers to patients with high-grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG.

Superficial Bladder Cancer

Ferring Pharmaceuticals157 participantsStarted Sep 2016

Gilbert, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +31 more locations

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Find Trials by Condition in Pittsburgh

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Episealer® Knee System IDE Clinical Study

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Investigation of Genetic Determinants of Capecitabine Toxicity

Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer